Welcome to isctr.org

 

Consensus Summit Keynote Speaker

Robert Califf, MD, MACC, will present the Keynote Address at the 2016 Consensus Summit being held October 29, 2016, in Washington, DC, in conjunction with TCT 2016. “We are excited to welcome the new commissioner of the FDA to address this summit, which will focus on creating a consensus document for a translational pathway for future cardiovascular device development that incorporates industry, FDA, and CMS input for cardiovascular disease,” said Nabil Dib, MD, president of the ISCTR.

As the top official of the Food and Drug Administration, Dr. Califf is committed to strengthening programs and policies that enable the agency to carry out its mission to protect and promote the public health. Previously, Dr. Califf served as the FDA’s Deputy Commissioner for Medical Products and Tobacco from February 2015 until his appointment as commissioner in February 2016. In that capacity, he provided executive leadership to the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, the Center for Devices and Radiological Health, and the Center for Tobacco Products. He also oversaw the Office of Special Medical Programs and provided direction for cross-cutting clinical, scientific, and regulatory initiatives, including precision medicine, combination products, orphan drugs, pediatric therapeutics, and the advisory committee system.

Prior to joining the FDA, Dr. Califf was a professor of medicine and vice chancellor for clinical and translational research at Duke University. He also served as director of the Duke Translational Medicine Institute and founding director of the Duke Clinical Research Institute. A nationally and internationally recognized expert in cardiovascular medicine, health outcomes research, healthcare quality, and clinical research, Dr. Califf has led many landmark clinical trials and is one of the most frequently cited authors in biomedical science, with more than 1,200 publications in the peer-reviewed literature.

Dr. Califf has served on the Institute of Medicine (IOM) committees that recommended Medicare coverage of clinical trials and the removal of ephedra from the market, as well as on the IOM Committee on Identifying and Preventing Medication Errors and the IOM Health Sciences Policy Board. He has served as a member of the FDA Cardiorenal Advisory Panel and FDA Science Board’s Subcommittee on Science and Technology. Dr. Califf has also served on the Board of Scientific Counselors for the National Institutes of Health and the National Library of Medicine, as well as on advisory committees for the National Cancer Institute, the National Heart, Lung, and Blood Institute, the National Institute of Environmental Health Sciences and the Council of the National Institute on Aging.

While at Duke, Dr. Califf led major initiatives aimed at improving methods and infrastructure for clinical research, including the Clinical Trials Transformation Initiative (CTTI), a public-private partnership co-founded by the FDA and Duke. He also served as the principal investigator for Duke’s Clinical and Translational Science Award and the NIH Health Care Systems Research Collaboratory coordinating center.

Dr. Califf is a graduate of Duke University School of Medicine. He completed a residency in internal medicine at the University of California, San Francisco and a fellowship in cardiology at Duke.

Dr. Nelson began his career as a surgeon, practicing in Minneapolis, Minnesota, at the Park Nicollet Medical Center. He first joined this large, multi-specialty group in 1969, and then served as chairman, president, and chief executive officer from 1975 through 1986. He also began his service on the board of Medtronic in 1980. According to Douglas Zipes, MD, past president of the American College of Cardiology, “There are many tall men in medicine but very few giants. Glen Nelson, who started out as a surgeon, joined the board of Medtronic and himself fostered a great deal of translational research. In 1980, Medtronic had been primarily a bradycardia company, heavily invested in pacemakers, and at that point, Medtronic transitioned into the tachycardia world, in part led by innovative insights by Glen Nelson. Glen was on the board of Medtronic for some 22 years – during that time, he helped innovate translational research at Medtronic.”

Cardiovascular Translational Research eTextbook

isctr-home-page-etextbook-ipad

Available now for iPad and web browsers.

Click to Subscribe

Upcoming ISCTR Summit On Cardiovascular Devices

The Translational Pathways for Cardiovascular Devices;
Current and Future Direction

Walter E. Washington Convention Center
Washington, DC

from 7:00am – 5:00pm EST
in Room 146A

 

October 29th, 2016

Click for program
ISCTR Symposium

View presentations from the 9th Annual ISCTR Symposium

Click to view

Become an ISCTR Member

Click to join

In Translation

Our new publication — hot off the press!

Click for the latest issue

Clinical Trials

Find announcements and information about upcoming and existing clinical trials, as well as links to other sources on the internet…

Symposium

9th Annual Symposium summary information and presentation videos …

In the News

Check here for our latest press releases and media contact information …

ISCTR

International Society for
Cardiovascular Translational Research

The International Society for Cardiovascular Translational Research (ISCTR) is a non-profit organization that was founded in 2007 by Dr Nabil Dib with a goal to expedite scientific discovery to clinical application (patients).

Read more…

The Glen and Marilyn Nelson Award for Innovation and Translation in Cardiovascular Medicine

nelsons-1

Click to view ->

Journal of Cardiovascular Translational Research

jctr-journal

Click for details on Springer…